Reviewing Profusa (NASDAQ:PFSA) and Check-Cap (NASDAQ:MBAI)

Profusa (NASDAQ:PFSA) and Check-Cap (NASDAQ:MBAI) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Profusa and Check-Cap, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Check-Cap	1	0	0	0	1.00

Profitability

This table compares Profusa and Check-Cap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Check-Cap	N/A	N/A	N/A

Volatility and Risk

Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Profusa and Check-Cap”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100,000.00	10.45	-$35.82 million	($169.72)	0.00
Check-Cap	N/A	N/A	$4.14 million	($2.77)	-0.50

Check-Cap has lower revenue, but higher earnings than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.